ADDMEDICA Receives FDA-Approval for Orphan Drug Siklos®, First and Sole Hydroxyurea-Based Treatment* for Paediatric Patients with Sickle Cell Anaemia.
ADDMEDICA has announced that the US Food and Drug Administration (FDA) has approved Siklos® (hydroxyurea tablets) in paediatric patients, two years of age and older, suffering from sickle cell anaemia.
Approval was obtained under a priority review and orphan drug designation.
Particularly suitable for paediatric populations, Siklos® offers dosing options to facilitate adjustment based on the patient’s weight to obtain the best efficacy/tolerance ratio for each child throughout the growth years.
FDA-approval of Siklos® was granted based on efficacy and safety data collected in a cohort study, Escort-HU, which included several hundred child and adult patients treated with Siklos® in Europe.
According to François Anger, President of ADDMEDICA:
“FDA-approval of Siklos® is a major breakthrough in the treatment of American children with sickle cell anaemia. European patients have been benefitting from Siklos®, the only form of hydroxyurea indicated in paediatric care in the world, since 2007. This successful outcome can also be attributed to the patients who agreed to participate in the Escort-HU study and the physicians who allowed it to happen. With the new FDA-approval, ADDMEDICA consolidates its leadership in the treatment of sickle cell anaemia by continuing to invest in the development and availability of this essential therapeutic product in new countries.”
Siklos® will be marketed in the United States by Medunik USA Inc.
“We’re pleased to partner with ADDMEDICA to distribute this orphan drug which is recognised as the reference drug treatment in sickle cell anaemia. It will improve the health and quality of life of hundreds of children with the disease in the United States,” said Éric Gervais, Executive Vice-President of Medunik. “The launch of Siklos® in the next few months establishes our footprint in the United States in orphan drug therapies and is the latest in a series of significant milestones for the company.”
About sickle cell anaemia
Sickle cell anaemia is a particularly disabling disease, whose most common acute manifestations are painful vaso-occlusive crises in the bones, lungs (acute chest syndrome) and most vascularised organs, and strokes. It may be life-threatening, especially in the case of acute chest syndrome.
The disease is caused by abnormal haemoglobin molecules causing red blood cells to become stiff and sickle-shaped under certain conditions whence the name of sickle-cell anaemia.
These sickled red blood cells tend to pile together, creating clots, and blocking the flow of blood through vessels and thus causing vaso-occlusive crises.
The disease is accompanied by varying degrees of anaemia and chronic complications may appear that affect various organs, e.g. hepatic or renal impairment and retarded growth.
The clinical expression of the disease and its evolution are highly variable among individuals.
Painful vaso-occlusive crises are the most common cause of hospitalisation in sickle cell anaemia patients, and therefore represent a very high cost for society.
Hydroxyurea is currently recognised as the reference drug treatment for this disease.
Approximately 100,000 persons suffer from sickle cell anaemia in the USA compared with approximately 60,000 in Europe. In both cases, it is considered to be a rare disease (less than 5 cases per 10,000 inhabitants)
Founded in 2005, ADDMEDICA is a pharmaceutical company based in France, focused on developing and marketing medical products for rare diseases and unmet medical needs. ADDMEDICA’s main therapeutic and development fields are
• Genetic diseases and their treatment,
• Organ transplant and tissue replacement,
• Wound healing and tissue regeneration.
ADDMEDICA developed Siklos® specifically for sickle cell anaemia. In 2007, ADDMEDICA obtained a marketing authorisation in Europe for Siklos®, the first and sole medicinal product indicated in the prevention of recurrent painful vaso-occlusive crises in sickle cell anaemia. ADDMEDICA now has FDA-approval for Silos® in the treatment of sickle cell disease in paediatric patients 2 years of age and older. Based on its expertise in the field, ADDMEDICA is pursuing the international development of Siklos®.
For more information: http://www.addmedica.com
About Medunik USA
Based in Pennsylvania, Medunik USA works to improve the health and quality of life of Americans living with rare diseases by making several orphan drug therapies available in the United States. With strategic partnerships worldwide, the company has critical experience in approval and market access processes as well as the marketing of orphan drug therapies. For more information: www.medunikusa.com.
Concerning the disease
Concerning Siklos® in the USA
Concerning Siklos® in Europe
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Amazon Studios Greenlights Utopia, Signs Gillian Flynn to Overall Deal19.4.2018 13:00 | Pressemelding
(NASDAQ: AMZN)— Amazon Studios announced today that it has greenlit a straight-to-series order for Utopia, a nine-episode series from award-winning Gillian Flynn, the best-selling author and screenwriter of Golden Globe nominated Gone Girl and HBO’s highly anticipated Sharp Objects. Flynn has also inked an overall deal with Amazon Studios across television, marking Utopia as the first project. Utopia will be available exclusively on Prime Video in more than 200 countries and territories. Utopia is based on the British series of the same name written by Dennis Kelly. The series is a co-production between Endemol Shine North America and Kudos, an Endemol Shine Group UK production studio, and Amazon Studios. A group of young adults, who meet online, are mercilessly hunted by a shadowy deep state organization after they come in to possession of a near mythical cult underground graphic novel – they discover the conspiracy theories in the comic’s pages may actually be real and are forced in
Yourtyres.co.uk at The Tire Cologne 2018: Concepts for Linking Online and Offline Business19.4.2018 12:47 | Pressemelding
Delticom AG/Yourtyres.co.uk. At this year’s Tire Cologne trade fair, Yourtyres.co.uk will be presenting its partnership model, which focuses on the linking of online and offline trade. Yourtyres.co.uk is the online wholesale shop from Europe’s largest tyre retailer, Delticom. From 29th May to 1st June, visitors to the fair can learn how workshops and stationary tyre retailers are able to benefit from the increasing amount of online trade without having to give up their independence. This is because Yourtyres.co.uk offers its wholesale customers excellent terms of purchase and high flexibility. There are no minimum purchase levels, and customers are not obliged to stock specific brands. There are also no contract costs or commissions. Using the Yourtyres.co.uk website and placing orders are completely free of charge. Customers benefit from the shop’s wide range of car, truck and motorbike tyres, as well as high availability all year round thanks to Delticom’s in-house warehousing and in
Flowsion A/S Wins Horizon 2020 SME Instrument Grant for Automatic Glucose Control in Intensive Care Medicine19.4.2018 11:48 | Pressemelding
Flowsion, the Denmark-based developer of continuous blood glucose systems for intensive care medicine, has won a prestigious European Commission Horizon 2020 SME Instrument award. The grant was awarded to assist in the development of an innovative automatic blood glucose control system, Glucostat, developed by Flowsion. Glucostat is expected to reduce mortality, morbidity, length of stay and treatment costs dramatically for intensive care patients compared to existing technologies. “It’s a welcome validation of our innovative, patented technology and a confirmation that we are addressing a really significant problem with a globally-relevant market opportunity,” said Hans Jorgen Pedersen, CEO of Flowsion. “Flowsion has already performed clinical studies with the system so we now that Glucostat will fulfil the demands of the intensive care units.” With 5-8 % success rate the European Innovation Council SME Instrument awards are exceptionally competitive, and only 3018 companies across Eu
Nexperia Secures $800M Financing to Fund Future Growth Plans19.4.2018 09:33 | Pressemelding
Nexperia, the global leader in discretes, logic and MOSFET devices, today announced the successful completion of a refinancing of its current facilities with USD 800 million equivalent of senior credit facilities. This includes a significant proportion of Revolving Credit facility. The proceeds will be used to refinance existing outstanding debt and for Capex expenditure to fund future growth. The facilities were arranged by Bank of America Merrill Lynch and HSBC, acting as Global Coordinators, and were syndicated by a group of nine global banks. The refinancing is fully supported by JAC Capital and Wise Road Capital, Nexperia’s two main shareholders, and provides a flexible financing package at very attractive terms to support the further growth of Nexperia going forward. Comments from Frans Scheper, Nexperia’s CEO: “This is the first time that Nexperia has approached the financial markets as an independent company, so we are very pleased with the enthusiastic response. Refinancing th
Grundig – Redefining Kitchen Design and Technology19.4.2018 09:19 | Pressemelding
UNLEASH YOUR GOURMET CAPABILITIES WITH GRUNDIG’S GOURMET CHEF™ OVEN This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180419005580/en/ (Photo: Grundig) Grundig’s Gourmet Chef™ Oven makes cooking elaborate, delicious meals easier than ever before. The oven’s intuitive design and innovative technology combine to simplify cooking and cleaning processes, inspire culinary creativity, and produce exquisite results. Equipped with advanced connected technologies and sensors, it allows users to precisely control the temperature of their food as it cooks to ensure the best results. This includes a high temperature moisture sensor, a temperature control sensor and BLDC motor, an integrated camera and a multipoint meat probe. Cleaning up after your culinary creation couldn’t be easier for users, with the oven fitted with advanced automatic self cleaning, including water and high-pressure steam cleaning, The Gourmet Chef™ elegant and sophis
PIXID Continues European Expansion with Acquisition of Dutch Staffing CRM Supplier Carerix19.4.2018 09:09 | Pressemelding
European workforce management solutions provider PIXID, has acquired Carerix, a Dutch-based CRM and ATS supplier, to further strengthen its proposition and expand its operations. Adding a leading supplier for CRM and ATS systems to its ranks allows PIXID to reinforce its expertise, enhance its service offering and strengthen the value chain offered to the temporary employment sector. The purchase also means PIXID can now add a presence in Benelux to its existing offices in France, in the UK (since its acquisition of The Internet Corporation in 2017) and its operations in Germany. A complete online software solution for recruitment and staffing agencies, Carerix is currently helping more than 10,000 users every day. It has a presence in 17 countries due to high-profile relationships with major customers including Randstad, Adecco, Manpower, T-Groep and DPA. Carerix has a multi-level partnership programme and an ecosystem which allows for a tailored offering and broader promotion of its